Get 30% Free Customization on This Report

Published Date: October, 2019

Hemato Oncology Testing Market (Products & Services - Assay Kits, and Services; Cancer - Leukemia, Non-hodgkin Lymphoma, and Other Cancers; Technology - PCR, NGS, IHC, and Other Technologies; End-user - Clinical Laboratories, Hospitals, and Other End-users): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025


Request Discount Enquire Before Buying

A recent report published by Infinium Global Research on hemato oncology testing market provides an in-depth analysis of segments and sub-segments in the global as well as regional hemato oncology testing market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional hemato oncology testing market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global hemato oncology testing market. According to the report, the global hemato oncology testing market is projected to grow at a CAGR of 14.5% over the forecast period of 2019-2025.

 

Market Insight

Hemato Oncology includes diseases such as hemophilia, sickle cell disease, iron deficiency anemia, thalassemias, leukemias and lymphomas, and cancers of other organs. Companies operating in the global hemato oncology testing market are investing in research and development to encourage innovations. The leading players operating in the global hemato oncology testing market are adopting strategies such as mergers, acquisitions, and new product launches that propel their market share.

 

The growing awareness about personalized medicines drives the growth of the hemato oncology testing market. The increasing cases of hematologic cancer contribute to the growth of the hemato oncology testing market. The surge in the number of collaborations to develop new assays stimulates the growth of the hemato oncology testing market. The increasing geriatric population worldwide boosts the growth of the hemato oncology testing market. In addition, hemato oncologists are gaining key knowledge of cancer genetics to assess the prognosis of their patients that stimulates the growth of the hemato oncology testing market. On the other side, uncertain reimbursement scenario in various regions hinders the growth of hemato oncology testing market. Moreover, research and development in hemato oncology testing create several opportunities for the growth of the hemato oncology testing market.

 

Based on geography, the global hemato oncology testing market is classified into North America, Asia-Pacific, Europe, and the Rest of the World. North America is expected to have a premium share in the global hemato oncology testing market. The increasing adoption of advanced treatment technologies and products in North America stimulates the growth of the hemato oncology testing market in North America. Asia-Pacific region is anticipated to grow in the global hemato oncology testing market with a significant CAGR over the forecast period. The large patient population present in the Asia-Pacific region contributes to the growth of the hemato oncology testing market in the Asia-Pacific region. Europe is showing growth in the global hemato oncology testing market.

 

Segment Covered

The report on the global hemato oncology testing market covers segments such as products & services, cancer, technology, and end-user. On the basis of products & services, the sub-markets include assay kits, and services. On the basis of cancer, the sub-markets include leukemia, non-hodgkin lymphoma, and other cancers. On the basis of technology, the sub-markets include PCR, NGS, IHC, and other technologies. On the basis of end-user, the sub-markets include clinical laboratories, hospitals, and other end-users.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., F. Hoffman-La Roche AG, QIAGEN NV, Arup Laboratories Inc., Bio-Rad Laboratories, Inc., ArcherDx, Inc., Asuragen, Inc., Invivoscribe Technologies, Inc., and other companies.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of hemato oncology testing market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. 

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.

sign up for our newsletter